Spero Therapeutics to Present at Upcoming Investor Conference
September 07 2022 - 8:05AM
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset
clinical-stage biopharmaceutical company focused on identifying,
developing and commercializing treatments in high unmet need areas
involving rare diseases and multi-drug resistant (MDR) bacterial
infections, today announced that Ankit Mahadevia, M.D., President
and Chief Executive Officer of Spero Therapeutics, will present and
be available for one-on-one meetings at the 24th Annual H.C.
Wainwright Global Investment Conference, which is taking place
September 12-14, 2022. Details for the presentation are as follows:
24th
Annual H.C. Wainwright Global Investment
Conference Conference Location: Lotte New York Palace
Hotel, New York, NY. Presentation Format: Corporate
PresentationPresentation Date & Time: Monday, September 12,
2022, at 3:30 PM ETWebcast link:
https://journey.ct.events/view/d64265b3-acb7-4c51-bb98-b85beb432e2b
Webcasts of the presentations may also be
accessed through Spero Therapeutics’ website
(www.sperotherapeutics.com) on the “Events and Presentations” page
under the “Investors and Media” tab. A replay of the presentations
will be available on the website following the conclusion of the
event.
About Spero TherapeuticsSpero
Therapeutics is a multi-asset, clinical-stage
biopharmaceutical company focused on identifying, developing, and
commercializing novel treatments for bacterial infections,
including multi-drug resistant bacterial infections and rare
diseases.
- Spero Therapeutics is
developing SPR720 as a novel oral therapy candidate for the
treatment of a rare, orphan pulmonary disease caused by
non-tuberculous mycobacterial infections.
- Spero Therapeutics also has an
IV-administered next generation polymyxin product candidate,
SPR206, developed from its potentiator platform, which is in
development to treat multi-drug resistant Gram-negative infections
in the hospital setting.
- Tebipenem HBr is an investigational
drug in the United States being developed for the treatment of
cUTI, including pyelonephritis, caused by certain microorganisms,
in adult patients who have limited treatment options; tebipenem HBr
is not FDA-approved.
For more information,
visit https://sperotherapeutics.com.
Investor Relations Contact: Ted
JenkinsVice President, Investor Relations and Strategic
FinanceIR@sperotherapeutics.com (617) 798-4039
Media Inquiries:
media@sperotherapeutics.com
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Apr 2023 to Apr 2024